Brisbane, Australia, 4 August 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is today pleased to announce SleepCheck, ResApp’s direct-to-consumer smartphone application for the self-assessment of sleep apnoea, is now available in the App Store for iPhone in 36 countries.
SleepCheck is a smartphone application that uses the microphone on an iPhone to record and analyse an adult’s breathing and snoring patterns overnight. In a large clinical study, SleepCheck’s algorithms were shown to accurately assess a person’s risk of sleep apnoea when compared to a full sleep test. SleepCheck is a mobile medical application that is CE Marked in Europe and TGA approved for ARTG listing in Australia.
Sleep apnoea is a common sleep breathing disorder where the person repeatedly stops breathing or has periods of shallow breathing during sleep. Globally, it has been estimated that 936 million people have sleep apnoea and up to 80% of people suffering from moderate or severe sleep apnoea are undiagnosed.
“We are excited to expand the availability of SleepCheck to a total of 36 countries, covering a population of nearly a half a billion people,” said Tony Keating, CEO and Managing Director. “SleepCheck is now translated into local languages in the European countries with the highest prevalence of sleep apnoea, including Germany, France and Spain, and we will continue to build out localised information for users. Undiagnosed sleep apnoea is a global issue, and SleepCheck offers consumers the only clinical grade, regulatory-approved screening app able to accurately assess their risk of sleep apnoea.”
SleepCheck version 1.3 is now available in English, German, French, Portuguese, Spanish and Italian and is available to purchase in the App Store for iPhone throughout Europe (including the United Kingdom), Australia, New Zealand, Hong Kong and Singapore. In addition to translations, SleepCheck v1.3 now saves the user’s age, gender and neck size for easier repeat testing, and provides additional educational material on sleep apnoea, its symptoms and risks, and treatment options.
About Sleep Apnoea
Sleep apnoea is a common sleep disorder where the person repeatedly stops breathing or has periods of shallow breathing during sleep. Data from the Wisconsin Sleep Cohort Study showed that sleep apnoea affects more than three in ten men and nearly two in ten women. 80 percent of people suffering moderate and severe sleep apnoea are undiagnosed. Untreated, obstructive sleep apnoea is known to increase the risk of heart disease, hypertension, stroke and type 2 diabetes, and is estimated by the American Academy of Sleep Medicine to cost the US economy $149.6 billion annually.
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.